Top

Published in:

01-04-2013 | Research

Expression Patterns of Thymosin β4 and Cancer Stem Cell Marker CD133 in Ovarian Cancers

Authors: Yong-Il Ji, Bo-Young Lee, Yun-Jeong Kang, Jin-Ok Jo, Sang Ho Lee, Heung Yeol Kim, Young-Ok Kim, Chulmin Lee, Suk Bong Koh, Ari Kim, Ji Young Lee, Min Hyung Jung, Mee Sun Ock, Hee-Jae Cha

Published in: Pathology & Oncology Research | Issue 2/2013

Abstract

Thymosin β4 (Tβ4), a small acidic actin binding peptide, is overexpressed in a side population of cancer stem cells and CD133-positive colorectal cancer stem cells. In order to understand the relationship between Tβ4 and CD133, we studied the expression patterns of Tβ4 and CD133 in ovarian cancers. The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry. Expression patterns and co-localization of Tβ4 and CD133 were examined by immunofluorescence and confocal laser-scanning microscopy. Tβ4 is overexpressed in primary ovarian cancers, but not in primary stomach cancers, when compared with normal controls. However, Tβ4 levels in metastatic stomach cancers to the ovary are significantly upregulated compared with levels in normal stomachs and primary stomach cancers. These results suggest that Tβ4 levels are related to tumorigenesis in ovarian cancers and metastasis in stomach cancers. The expression of Tβ4 in normal ovaries and normal stomachs was weak, but was co-localized with CD133 expression. Tβ4 expression was also co-localized with CD133 expression in primary ovarian carcinomas, metastatic ovarian cancers from stomach cancers and primary stomach cancers. These data suggest that Tβ4 expression is strongly related to CD133 expression and is a characteristic of stem cells or cancer stem cells.

Low TL, Goldstein AL (1982) Chemical characterization of thymosin beta 4. J Biol Chem 257:1000–1006PubMed

Safer D, Golla R et al (1990) Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets. Proc Natl Acad Sci U S A 87:2536–2540PubMedCrossRef

Safer D, Elzinga M et al (1991) Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 266:4029–4032PubMed

Cassimeris L, Safer D et al (1992) Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol 119:1261–1270PubMedCrossRef

Van Troys M, Dewitte D et al (1996) The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J 15:201–210PubMed

Grant DS, Rose W et al (1999) Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis 3:125–135PubMedCrossRef

Malinda KM, Goldstein AL et al (1997) Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 11:474–481PubMed

Malinda KM, Sidhu GS et al (1999) Thymosin beta4 accelerates wound healing. J Invest Dermatol 113:364–368PubMedCrossRef

Philp D, Nguyen M et al (2004) Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J 18:385–387PubMed

10.

Philp D, Goldstein AL et al (2004) Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev 125:113–115PubMedCrossRef

11.

Philp D, St-Surin S et al (2007) Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci 1112:95–103PubMedCrossRef

12.

Hall AK (1994) Molecular interactions between G-actin, DNase I and the beta-thymosins in apoptosis: a hypothesis. Med Hypotheses 43:125–131PubMedCrossRef

13.

Iguchi K, Usami Y et al (1999) Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs. Biochem Pharmacol 57:1105–1111PubMedCrossRef

14.

Niu M, Nachmias VT (2000) Increased resistance to apoptosis in cells overexpressing thymosin beta four: a role for focal adhesion kinase pp125FAK. Cell Adhes Commun 7:311–320PubMedCrossRef

15.

Moon EY, Song JH et al (2007) Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death. Oncol Res 16:507–516PubMedCrossRef

16.

Young JD, Lawrence AJ et al (1999) Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 5:1424–1427PubMedCrossRef

17.

Sosne G, Qiu P et al (2007) Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res 84:663–669PubMedCrossRef

18.

Larsson LI, Holck S (2007) Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment. Hum Pathol 38:114–119PubMedCrossRef

19.

Santelli G, Califano D et al (1999) Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol 155:799–804PubMedCrossRef

20.

Hall AK (1991) Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer 48:672–677PubMedCrossRef

21.

Ji P, Diederichs S et al (2003) MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22:8031–8041PubMedCrossRef

22.

Wang WS, Chen PM et al (2004) Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23:6666–6671PubMedCrossRef

23.

Kobayashi T, Okada F et al (2002) Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells. Am J Pathol 160:869–882PubMedCrossRef

24.

Cha HJ, Jeong MJ et al (2003) Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95:1674–1680PubMedCrossRef

25.

Huang HC, Hu CH et al (2007) Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26:2781–2790PubMedCrossRef

26.

Ricci-Vitiani L, Pagliuca A et al (2008) Colon cancer stem cells. Gut 57:538–548PubMedCrossRef

27.

Kondo T, Setoguchi T et al (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 101:781–786PubMedCrossRef

28.

Ricci-Vitiani L, Lombardi DG et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115PubMedCrossRef

29.

Huang EH, Hynes MJ et al (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389PubMedCrossRef

30.

Liu G, Yuan X et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67PubMedCrossRef

31.

Shmelkov SV, Butler JM et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120PubMed

32.

Miraglia S, Godfrey W et al (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021PubMed

33.

Yin AH, Miraglia S et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012PubMed

34.

Singh SK, Clarke ID et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

35.

Singh SK, Hawkins C et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401PubMedCrossRef

36.

Collins AT, Berry PA et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951PubMedCrossRef

37.

Suetsugu A, Nagaki M et al (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820–824PubMedCrossRef

38.

Yin S, Li J et al (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120:1444–1450PubMedCrossRef

39.

Hermann PC, Huber SL et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323PubMedCrossRef

40.

Eramo A, Lotti F et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514PubMedCrossRef

41.

O’Brien CA, Pollett A et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110PubMedCrossRef

42.

Todaro M, Alea MP et al (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389–402PubMedCrossRef

43.

Steiniger SC, Coppinger JA et al (2008) Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 26:3037–3046PubMedCrossRef

44.

Ricci-Vitiani L, Mollinari C et al (2010) Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J 24:4291–4301PubMedCrossRef

45.

Piek JM, van Diest PJ et al (2008) Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol 622:79–87PubMedCrossRef

46.

Bridda A, Padoan I et al (2007) Peritoneal mesothelioma: a review. MedGenMed 9:32PubMed

47.

Jo JO, Kang YJ et al (2011) Thymosin beta4 expression in human tissues and in tumors using tissue microarrays. Appl Immunohistochem Mol Morphol 19:160–167PubMedCrossRef

48.

Vermeulen L, Sprick MR et al (2008) Cancer stem cells–old concepts, new insights. Cell Death Differ 15:947–958PubMedCrossRef

49.

Hollier BG, Evans K et al (2009) The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14:29–43PubMedCrossRef

50.

Wang ZY, Zeng FQ et al (2010) Evaluation of thymosin beta4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma. Urol Oncol 30:167–176PubMed

Title: Expression Patterns of Thymosin β4 and Cancer Stem Cell Marker CD133 in Ovarian Cancers
Authors: Yong-Il Ji
Bo-Young Lee
Yun-Jeong Kang
Jin-Ok Jo
Sang Ho Lee
Heung Yeol Kim
Young-Ok Kim
Chulmin Lee
Suk Bong Koh
Ari Kim
Ji Young Lee
Min Hyung Jung
Mee Sun Ock
Hee-Jae Cha
Publication date: 01-04-2013
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2013
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-012-9574-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

MT1 Melatonin Receptor Expression in Warthin’s Tumor

Correlation Between Immunophenotype Classification and Clinicopathological Features in Chinese Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

Chemopreventive Efficacy of Naringenin-Loaded Nanoparticles in 7,12-dimethylbenz(a)anthracene Induced Experimental Oral Carcinogenesis

Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC

Altered p16 and Bcl-2 Expression Reflects Pathologic Development in Hydatidiform Moles and Choriocarcinoma

4-1BB Protects Dendritic Cells from Prostate Cancer-Induced Apoptosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer